YEEHAW CANDIDATES Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sergio H who wrote (5953)	11/23/2004 10:48:43 AM
From: Gulo	Read Replies (1) of 23958

I may have found a candidate - NEOL. I am just beginning my DD, but a new release yesterday sound promising. "Dr. Sampson's clinical study was based on observations to date from NeoPharm's other Phase I/II IL13-PE38QQR clinical trials indicating an increase in median survival is associated with optimal (70.3 weeks) vs. sub-optimal (41.4 weeks) catheter placement in the peritumoral setting. The median survival for this same patient population, according to publications of clinical studies with other treatments, is 20-26 weeks. " biz.yahoo.com The company appears to have a decent pipeline, of other drugs as well, although they all hinge on the liposome delivery system. I'm in for a handful of shares at 10.20. -g

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next